Potential consolidation therapies for Hodgkin’s Lymphoma patients

Dr Anna Sureda from the Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain discusses the standard of care for Hodgkin’s Lymphoma and potential consolidation therapies. Most patients with Hodgkin’s Lymphoma are cured with first-line chemotherapy however, a small proportion of patients are non-responders or relapse, who have to undergo an autologous stem cell transplant. However, approximately 50% of patients relapse after transplantation. As a result, drugs are being tested to improve the rate of relapse after second-line treatment, and one study demonstrated a reduction in relapse rates after receiving a monoclonal antibody as consolidation therapy. Recorded at the annual meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Marseille, France.